MedPacto to present the abstract about the combination study of Vactosertib in pancreatic cancer at the American Society of Clinical Oncology Annual Meeting
May 27, 2022
Phase1b clinical trial of Vactosertib in combination with FOLFOX for patients with pancreatic cancer when first-line gemcitabine/nab-paclitaxel treatment has failed
[2022-05-27] MedPacto, a genome-based drug discovery and clinical-stage biotechnology company, announced that an abstract of a combination study with Vactosertib in the patients with pancreatic cancer will be released at the upcoming annual meeting of the Amerian Society of Clinical Oncology (ASCO.)
ASCO, taking place June 3-7, 2022 in Chicago, Illinois, is one of the most noteworthy oncology conferences in the world. The global academic conference attracts more than 40,000 attendees from around the world including cancer physicians and representatives of global pharmaceutical companies from 70 different countries, presenting a wide range of clinical outcomes of new drug development for cancer treatments.
MedPacto’s upcoming release is about the Phase1b clinical trial of Vactosertib in combination with FOLFOX for patients with pancreatic cancer when first-line gemcitabine/nab-paclitaxel treatment has failed.
After having been administered a combination therapy of Vactosertib with FOLFOX, a total of 16 patients with pancreatic cancer have shown significantly improved clinical outcomes, demonstrating 23.1% of objective response rate (ORR), 38.5% of stable disease (SD), 61.5% of Clinical benefit, and 5.6 months of median progression-free survival (mPFS), with similar safety profiles when compared to the standard therapy.
Normally, for pancreatic cancer treatment, the mPFS of standard-of-care in the first line is 4 months; whereas the FOLFOX for the second-line treatment for those patients who have failed with gemcitabine-based therapy is 1.7 months with 0% ORR.
Pancreatic cancer is notorious for its low response to anticancer drugs as its dense fibrotic stroma is interlaced with an extracellular matrix that inhibits the access of the anticancer drugs. Surgery is only viable if the cancer cells have not spread to other adjacent organs, with exception of the pancreas, and whether or not the patient is healthy enough to go through the surgery. However, in most cases, patients get delayed diagnoses, even in cases where the cancer is detected in the early stage when there are no symptoms. Besides, pancreatic cancer has a high recurrence rate, so chemotherapy plays a pivotal role in treatment.
“The updated release is a confirmative evidence supporting the clinical efficacy of Vactosertib for the treatment of pancreatic cancer in combination with FOLFOX. Thus, this outcome milestones forward to meet the expectation for the forthcoming commercialization of Vactosertib to benefit the pancreatic cancer patients” stated a MedPacto representative.